1. Scrip
  2. >>R&D

Syndax Sees Subgroup Efficacy For Entinostat Plus Keytruda In NSCLC

 
• By Joseph Haas

The company says a subgroup of lung cancer patients with high pre-treatment monocyte levels showed promising response and PFS rates in study pairing Syndax’s selective HDAC inhibitor with Merck’s Keytruda. Mature data will inform future Phase III melanoma plans.

female scientist working with microscope

Syndax Pharmaceuticals Inc. thinks it has identified a subgroup of non-small cell lung cancer (NSCLC) patients who respond well to treatment with entinostat and Merck & Co. Inc.’s Keytruda, and the company is designing a pivotal study it hopes to launch later this year in this biomarker-stratified patient subpopulation.

Syndax held an investor call May 17, following the release of abstracts for next month’s American Society of Clinical Oncology (ASCO) meeting, to outline some of the data it will present at the conference for its selective histone deacetylase (HDAC) inhibitor with

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Scrip

In Brief: Genmab To Seek FDA Nod For Epkinly In Lymphoma

 
• By Sushmita Panda

Genmab will submit an sBLA for Epkinly in R/R follicular lymphoma in H1 2025, backed by positive Phase III data.

Pharma Predicts Modest Impact From Tariffs, But It Depends On What Comes Next

 
• By Jessica Merrill

Drugmakers aren’t expecting a big financial hit from tariffs for now, but a report commissioned by PhRMA suggests the cost of pharma-sector tariffs could be steep.

OPPI’s Matai On Section 3(d) Of India’s Patent Regulations: Now’s The Time To Open Up

 
• By Anju Ghangurde

Anil Matai, director general, Organization of Pharmaceutical Producers of India, talks in this audio interview about the evolving intellectual property landscape in India post the 2024 amendments, including long-standing sticking points such as Section 3(d) of India’s patent regulations and innovator firms' experience of the Bolar provision. There’s also a "compelling reason" to consider regulatory data protection, he claims.